Evidence map›Paper›PMID 24966987›Full record

ArticleInternational journal of clinical and experimental pathology2014

A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.

Ranjit Nair, Shereen Gheith, Dan Popescu, Nicole M Agostino

Open access · greenAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ranjit NairDepartment of Internal Medicine, Lehigh Valley Hospital and Health Network Allentown, PA 18105, USA.
Shereen GheithDepartment of Pathology, Lehigh Valley Hospital and Health Network Allentown, PA 18105, USA.
Dan PopescuDepartment of Hematology/Oncology, Lehigh Valley Hospital and Health Network Allentown, PA 18105, USA.
Nicole M AgostinoDepartment of Hematology/Oncology, Lehigh Valley Hospital and Health Network Allentown, PA 18105, USA.
Lehigh Valley Hospital-Pocono · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lenalidomide belongs to a novel class of drugs called Immunomodulators which are now being used for the treatment of plasma cell dyscrasias with variable degrees of efficacy and toxicity. Though Second Primary Malignancies (SPM) have been a concern with its use, the benefits of the treatment outweigh the risks. The leukemogenic risk seems to be potentiated especially when combined with alkylating agents and the SPMs documented are predominantly myeloblastic. To date there are no reported cases of new lymphocytic leukemias in AL amyloidosis, regardless of whether undergone treatment or not. We present a case of AL amylodosis who was treated with lenalidomide and subsequently developed acute lymphoblastic leukemia.

Indexed as

AgedAmyloidosisAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBiopsyBirefringenceBone Marrow ExaminationFatal OutcomeFemaleHumansImmunoglobulin Light ChainsImmunologic FactorsLenalidomideMicroscopy, PolarizationPrecursor Cell Lymphoblastic Leukemia-LymphomaRecurrenceBiomarkersImmunoglobulin Light ChainsImmunologic FactorsLenalidomideThalidomideacute lymphoblastic leukemiaAL amyloidosislenalidomideSecond primary malignancy

Identifiers

PMID24966987
PMCPMC4069899
OpenAlexW199052022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.